Ion Beam Applications SA IBA ( (GB:0GZK) ) has issued an announcement.
IBA reported record-high revenue and a return to profitability for the 2024 financial year, driven by effective backlog conversion and growth in their Other Accelerators segment. The company achieved a 7% increase in net sales and a significant improvement in gross margin, reflecting strategic investments and operational efficiency. With a stable backlog of €1.5 billion and a strong balance sheet, IBA is well-positioned for future growth, supported by a new organizational structure and an updated mid-term outlook projecting a revenue CAGR of 5-7% through 2028.
More about Ion Beam Applications SA IBA
Ion Beam Applications SA (IBA) is a leading company in particle accelerator technology, specializing in the development and production of advanced proton therapy systems and other accelerator technologies. The company focuses on providing innovative solutions for cancer treatment and other medical applications, with a strong emphasis on research and development to drive future growth.
YTD Price Performance: -4.05%
Average Trading Volume: 1,069
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €382.5M
For a thorough assessment of 0GZK stock, go to TipRanks’ Stock Analysis page.